Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 3/20 | 0.66 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | CETP | P11597 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12312284 | 0.84 | AOC3 (0.46) | AOC3ACACBCETPIRAK4 | |
| SCHEMBL1971904 | 0.80 | AOC3 (0.68) | AOC3 | |
| SCHEMBL1972240 | 0.80 | AOC3 (0.74) | AOC3 | |
| SCHEMBL1970650 | 0.79 | AOC3 (1.00) | AOC3ACACBIRAK4 | |
| SCHEMBL1971623 | 0.79 | AOC3 (0.73) | AOC3 | |
| SCHEMBL1969842 | 0.78 | AOC3 (0.66) | AOC3 | |
| SCHEMBL1971755 | 0.78 | AOC3 (0.80) | AOC3 | |
| SCHEMBL1971938 | 0.78 | AOC3 (1.00) | AOC3 | |
| SCHEMBL1968586 | 0.78 | AOC3 (0.79) | AOC3 | |
| SCHEMBL1972052 | 0.77 | AOC3 (0.61) | AOC3ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10399973-B2 | Compounds I | Benevolentai Cambridge Limited (GB) | 2019-09-03 | — | — | US | claimed |
| US-20180118744-A1 | NEW COMPOUNDS I | PROXIMAGEN LIMITED (GB) | 2018-05-03 | — | — | US | claimed |
| US-20170044157-A1 | NEW COMPOUNDS I | PROXIMAGEN, LLC | 2017-02-16 | — | — | US | claimed |
| US-20160113893-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | UPSHER-SMITH LABORATORIES, INC. | 2016-04-28 | — | — | US | claimed |
| US-9035066-B2 | Method of using 4,5,6,7-tetrahydroimidazo[4,5-C]pyridine compounds | PROXIMAGEN LIMITED (GB) | 2015-05-19 | — | — | US | claimed |
| US-20140121219-A1 | New Compounds I | PROXIMAGEN LIMITED (GB) | 2014-05-01 | — | — | US | claimed |
| EP-2334672-B1 | 4,5,6,7-Tetrahydroimidazo[4,5-c]pyridine compounds as inhibitors of SSAO | PROXIMAGEN LTD (GB) | 2013-11-20 | — | — | EP | claimed |
| US-8569338-B2 | Methods of using 4, 5, 6, 7-tetrahydroimidazo-[4,5-c]pyridine compounds | PROXIMAGEN LTD. (GB) | 2013-10-29 | — | — | US | claimed |
| US-20120302583-A1 | New Compounds I | PROXIMAGEN LIMITED (GB) | 2012-11-29 | — | — | US | claimed |
| US-8263616-B2 | 4,5,6,7-tetrahydroimidazo[4,5-c]pyridine compounds | PROXIMAGEN LTD (GB) | 2012-09-11 | — | — | US | claimed |
| US-20110207746-A1 | NEW COMPOUNDS I | PROXIMAGEN LIMITED (GB) | 2011-08-25 | — | — | US | claimed |
| EP-2334672-A1 | NEW COMPOUNDS I | Proximagen Limited (GB) | 2011-06-22 | — | — | EP | claimed |
| WO-2010031789-A1 | NEW COMPOUNDS I | BIOVITRUM AB (PUBL) (SE) | 2010-03-25 | — | — | WO | claimed |
| US-11040969-B2 | Compounds I | Benevolentai Cambridge Limited (GB) | 2021-06-22 | — | — | US | disclosed |
| EP-3777846-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | BenevolentAI Cambridge Limited (GB) | 2021-02-17 | — | — | EP | disclosed |
| US-10399973-B2 | Compounds I | Benevolentai Cambridge Limited (GB) | 2019-09-03 | — | — | US | disclosed |
| US-8263616-B2 | 4,5,6,7-tetrahydroimidazo[4,5-c]pyridine compounds | PROXIMAGEN LTD (GB) | 2012-09-11 | — | — | US | disclosed |
| US-20110207746-A1 | NEW COMPOUNDS I | PROXIMAGEN LIMITED (GB) | 2011-08-25 | — | — | US | disclosed |
| EP-2334672-A1 | NEW COMPOUNDS I | Proximagen Limited (GB) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010031789-A1 | NEW COMPOUNDS I | BIOVITRUM AB (PUBL) (SE) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10399973-B2 | Compounds I | SSB, SQLE, ALOX15B | AOC3 63/4885ACACB 2232/4885CETP 3309/4885 |
| US-20160113893-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | VAPB, VAPA, AOX1 | AOC3 24/4885ACACB 957/4885CETP 4414/4885 |
| US-20110207746-A1 | NEW COMPOUNDS I | SSB, NFKBIA, ALOX15B | AOC3 54/4885ACACB 1959/4885CETP 3615/4885 |
| US-20120302583-A1 | New Compounds I | SSB, NFKBIA, NOD1 | AOC3 111/4885ACACB 2877/4885CETP 4146/4885 |
| US-11040969-B2 | Compounds I | SSB, SQLE, ALOX15B | AOC3 63/4885ACACB 2232/4885CETP 3309/4885 |
| US-20140121219-A1 | New Compounds I | SSB, NFKBIA, ALOX15B | AOC3 54/4885ACACB 1959/4885CETP 3615/4885 |
| US-20170044157-A1 | NEW COMPOUNDS I | SSB, NFKBIA, ALOX15B | AOC3 54/4885ACACB 1959/4885CETP 3615/4885 |
| US-20180118744-A1 | NEW COMPOUNDS I | SSB, NFKBIA, ALOX15B | AOC3 54/4885ACACB 1959/4885CETP 3615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.